KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Long-Term Debt Repayments (2017 - 2025)

Biogen (BIIB) has 10 years of Long-Term Debt Repayments data on record, last reported at $1.8 billion in Q2 2025.

  • For Q2 2025, Long-Term Debt Repayments rose 600.0% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, up 169.23%, while the annual FY2025 figure was $1.8 billion, 169.23% up from the prior year.
  • Long-Term Debt Repayments reached $1.8 billion in Q2 2025 per BIIB's latest filing, up from $250.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.8 billion in Q2 2025 and bottomed at -$1.0 billion in Q4 2022.
  • Average Long-Term Debt Repayments over 5 years is $321.0 million, with a median of $209.6 million recorded in 2021.
  • Peak YoY movement for Long-Term Debt Repayments: tumbled 489.53% in 2022, then surged 600.0% in 2025.
  • A 5-year view of Long-Term Debt Repayments shows it stood at -$170.0 million in 2021, then crashed by 489.53% to -$1.0 billion in 2022, then surged by 164.86% to $650.0 million in 2023, then tumbled by 61.54% to $250.0 million in 2024, then soared by 600.0% to $1.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $1.8 billion in Q2 2025, $250.0 million in Q2 2024, and $400.0 million in Q1 2024.